The U.S. Food and Drug Administration has approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumours overexpress the HER2 gene (HER2+).
Ogivri is the first biosimilar approved in the US for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.
The FDA's approval of Ogivri is based on a review of evidence that included extensive structural and functional characterisation, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Ogivri is biosimilar to Herceptin. Ogivri has been approved as a biosimilar, not as an interchangeable product.
Common expected side effects of Ogivri for the treatment of HER2+ breast cancer include a headache, diarrhoea, nausea, chills, fever, infection, congestive heart failure, difficulty sleeping (insomnia), cough and rash.
Common expected side effects of Ogivri for the treatment of HER2+ metastatic stomach cancer include low levels of certain white blood cells, diarrhoea, fatigue, low levels of red blood cells, inflammation of the mouth, weight loss, upper respiratory tract infections, fever, low levels of blood platelets, swelling of the mucous membranes, common cold and unusual taste sensation. Serious expected side effects of Ogivri include worsening of chemotherapy-induced neutropenia.